title: Tauopathies and synucleinopathies: do cerebrospinal fluid beta-amyloid peptides reflect disease-specific pathogenesis?
abstract: To evaluate variations in amyloid beta (Abeta) peptide pattern in cerebrospinal fluid (CSF) in neurodegenerative disorders. A recently established quantitative urea-based Abeta-sodium-dodecylsulfate-polyacrylamide-gel-electrophoresis with western immunoblot (Abeta-SDS-PAGE/immunoblot) revealed a highly conserved Abeta peptide (Abeta1-37, 1-38, 1-39, 1-40, 1-42) pattern in CSF. We asked whether the variation might be useful to further elucidate the overlap between or distinctions among neurodegenerative diseases in Abeta-processing. We used the Abeta-SDS-PAGE/immunoblot to investigate CSF for disease-specific Abeta peptide patterns. CSF samples from 96 patients with mainly clinically diagnosed Alzheimer's disease (n = 15), progressive supranuclear palsy (n = 20), corticobasal degeneration (n = 12), Parkinson's disease (n = 11), multiple systems atrophy (n = 18), and dementia with Lewy-bodies (n = 20) were analysed as well a comparison group (n = 19). The Abeta peptide patterns varied between tauopathies and synucleinopathies and between all diseases and the comparison group, possibly due to the influence of tau and alpha-synuclein on Abeta-processing.
authors.affiliation: Center for Neurologic Diseases, Department of Neurology, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, USA. bmollenhauer@rics.bwh.harvard.edu
authors.forename: B
authors.initials: B
authors.lastname: Mollenhauer
authors.forename: M
authors.initials: M
authors.lastname: Bibl
authors.forename: H
authors.initials: H
authors.lastname: Esselmann
authors.forename: P
authors.initials: P
authors.lastname: Steinacker
authors.forename: C
authors.initials: C
authors.lastname: Trenkwalder
authors.forename: J
authors.initials: J
authors.lastname: Wiltfang
authors.forename: M
authors.initials: M
authors.lastname: Otto
mesh_terms: D000368:Aged; D000369:Aged, 80 and over; D000544:Alzheimer Disease / Q000134:cerebrospinal fluid / Q000209:etiology* / Q000473:pathology*; D016229:Amyloid beta-Peptides / Q000096:biosynthesis / Q000134:cerebrospinal fluid* / Q000378:metabolism; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D019578:Multiple System Atrophy / Q000134:cerebrospinal fluid / Q000209:etiology / Q000473:pathology; D011499:Protein Processing, Post-Translational; D024801:Tauopathies / Q000134:cerebrospinal fluid / Q000209:etiology* / Q000473:pathology*; D051844:alpha-Synuclein / Q000134:cerebrospinal fluid* / Q000502:physiology; D016875:tau Proteins / Q000134:cerebrospinal fluid / Q000502:physiology
chemical_list: D016229:Amyloid beta-Peptides; D051844:alpha-Synuclein; D016875:tau Proteins